Australia's Invex Therapeutics drops on ending contract with Peptron

Peptron

22/12/2023 04:04

** Shares of Australia's Invex Therapeutics  IXC.AX  drop
2.4%
    ** Biopharmaceutical co terminates collaboration and
manufacturing agreement with Peptron  087010.KQ  after closing
clinical trial on IIH Evolve
    ** Shares of Peptron are up ~0.7%
    ** Says trial for treating Idiopathic Intracranial
Hypertension (IIH) or increased pressure in the brain
    ** Adds will provide Peptron with regulatory documents
related to the trial and grant Peptron an exclusive and
royalty-free license to commercialise Presendin in Korea and
China
    ** Including day's losses, IXC has fallen 41.7% this year
and is set for fifth year of decline, while Peptron is up over
360%

 (Reporting by Sneha Kumar in Bengaluru)
 ((Sneha.Kumar@thomsonreuters.com;))